Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

3 Zoekresultaten.

Effect of casoptiant on cardiac conduction as compared to placebo and moxifloxacin 103447 - Eligibility Question

- 17-09-21 - 1 Formulier, 4 Itemgroepen, 26 Data-elementen, 1 Taal

Itemgroepen: Administrative, Eligibility Question, Inclusion Criteria, Exclusion Criteria

Study ID: 103447 Clinical Study ID: NKV103447 Study Title:A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced

Study of Casopitant Pharmacokinetics in Healthy Males, NKV103933 - Eligibility Criteria

- 07-06-20 - 1 Formulier, 4 Itemgroepen, 31 Data-elementen, 1 Taal

Itemgroepen: Administrative Data, Eligibility Question, Inclusion Criteria, Exclusion Criteria

Study ID: 103933 Clinical Study ID: NKV103933 Study Title: A non-randomised, open label, two period cross-over study to determine the excretion balance and metabolic disposition of [14C]-GW679769, administered as single doses of an oral solution and an intravenous infusion to healthy male subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced Protocol ID: NKV103933 The eligibility to participate was determined during a screening visit within 21 days prior to first dosing day. The study consisted of two dosing periods, each consisting of predose visit, monitoring after dose administration and prior to discharge visit. Dosing periods were separated by a wash-out period of 43 days. The Eligibility Criteria Form has to be filled in at the screening visit. It determines the eligibility of the subject to participate in the study. Confirm that the subject is eligible to participate in the study and if not, that all the failed criteria have been marked.

Eligibility Multiple Myeloma NCT00306735

- 14-05-17 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.; ODM derived from: https://clinicaltrials.gov/show/NCT00306735

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.